---
figid: PMC3252376__ppat.1002468.g007
figtitle: Human Subtilase SKI-1/S1P Is a Master Regulator of the HCV Lifecycle and
  a Potential Host Cell Target for Developing Indirect-Acting Antiviral Agents
organisms:
- NA
pmcid: PMC3252376
filename: ppat.1002468.g007.jpg
figlink: /pmc/articles/PMC3252376/figure/ppat-1002468-g007/
number: F7
caption: (1) The inactive SKI-1/S1P zymogen is biosynthesized in the ER and traffics
  to the Golgi apparatus following intramolecular autocatalytic maturation of the
  proenzyme , , , . (2) During HCV infection, the SREBP pathway is activated by a
  variety of molecular mechanisms , –. (3) For SREBP to activate genes involved in
  lipid biosynthesis, its N-terminal domain must be released through sequential endoproteolytic
  cleavage first by SKI-1/S1P and then by S2P , . (4) The released N-terminal domain
  translocates to the nucleus and activates various aspects of lipid metabolism .
  (5) Activation of lipid biosynthesis increases LD formation where the HCV core protein
  localizes to orchestrate HCV assembly and subsequent secretion , , . (6) Biosynthesis
  of LDLR, a proposed receptor for HCV entry, is also activated by SREBP signaling
  , , . (7) Spn4A.RRLL(s) is a secretory pathway-expressed serpin (). (8) Spn4A.RRLL(s)
  interacts and forms a covalent complex with enzymatically active SKI-1/S1P molecules
  ( and ) in the Golgi apparatus preventing SKI-1/S1P-mediated endoproteolytic cleavage
  of SREBP protein (). (9) A small-molecule inhibitor PF-429242 also efficiently inhibits
  SKI-1/S1P endoproteolytic activity (). (10) SKI-1/S1P inhibition blocks expression
  of the putative HCV receptor, LDLR (4), and reduces HCV entry (). (11) The expression
  of other SREBP-regulated genes, such as PCSK9 and SREBP-2, are also blocked ().
  (12) Downstream lipid synthesis is interrupted resulting in overall reduced intracellular
  cholesterol-ester and triglyceride abundance (). (12) This is then detected as a
  decrease in LD abundance (), which impedes assembly and secretion of infectious
  HCV particles.
papertitle: Human Subtilase SKI-1/S1P Is a Master Regulator of the HCV Lifecycle and
  a Potential Host Cell Target for Developing Indirect-Acting Antiviral Agents.
reftext: Andrea D. Olmstead, et al. PLoS Pathog. 2012 Jan;8(1):e1002468.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8605827
figid_alias: PMC3252376__F7
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC3252376__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3252376__ppat.1002468.g007.html
  '@type': Dataset
  description: (1) The inactive SKI-1/S1P zymogen is biosynthesized in the ER and
    traffics to the Golgi apparatus following intramolecular autocatalytic maturation
    of the proenzyme , , , . (2) During HCV infection, the SREBP pathway is activated
    by a variety of molecular mechanisms , –. (3) For SREBP to activate genes involved
    in lipid biosynthesis, its N-terminal domain must be released through sequential
    endoproteolytic cleavage first by SKI-1/S1P and then by S2P , . (4) The released
    N-terminal domain translocates to the nucleus and activates various aspects of
    lipid metabolism . (5) Activation of lipid biosynthesis increases LD formation
    where the HCV core protein localizes to orchestrate HCV assembly and subsequent
    secretion , , . (6) Biosynthesis of LDLR, a proposed receptor for HCV entry, is
    also activated by SREBP signaling , , . (7) Spn4A.RRLL(s) is a secretory pathway-expressed
    serpin (). (8) Spn4A.RRLL(s) interacts and forms a covalent complex with enzymatically
    active SKI-1/S1P molecules ( and ) in the Golgi apparatus preventing SKI-1/S1P-mediated
    endoproteolytic cleavage of SREBP protein (). (9) A small-molecule inhibitor PF-429242
    also efficiently inhibits SKI-1/S1P endoproteolytic activity (). (10) SKI-1/S1P
    inhibition blocks expression of the putative HCV receptor, LDLR (4), and reduces
    HCV entry (). (11) The expression of other SREBP-regulated genes, such as PCSK9
    and SREBP-2, are also blocked (). (12) Downstream lipid synthesis is interrupted
    resulting in overall reduced intracellular cholesterol-ester and triglyceride
    abundance (). (12) This is then detected as a decrease in LD abundance (), which
    impedes assembly and secretion of infectious HCV particles.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LRP1
  - modSP
  - LpR2
  - mgl
  - S1P
  - Sk1
---
